These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 28566376)

  • 21. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.
    Liu YP; Steele MB; Suksanpaisan L; Federspiel MJ; Russell SJ; Peng KW; Bakkum-Gamez JN
    Gynecol Oncol; 2014 Jan; 132(1):194-202. PubMed ID: 24246772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiomic Profiling Identified EGF Receptor Signaling as a Potential Inhibitor of Type I Interferon Response in Models of Oncolytic Therapy by Vesicular Stomatitis Virus.
    Nikitina AS; Lipatova AV; Goncharov AO; Kliuchnikova AA; Pyatnitskiy MA; Kuznetsova KG; Hamad A; Vorobyev PO; Alekseeva ON; Mahmoud M; Shakiba Y; Anufrieva KS; Arapidi GP; Ivanov MV; Tarasova IA; Gorshkov MV; Chumakov PM; Moshkovskii SA
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncolytic vesicular stomatitis virus alone or in combination with JAK inhibitors is effective against ovarian cancer.
    Geoffroy K; Mullins-Dansereau V; Leclerc-Desaulniers K; Viens M; Bourgeois-Daigneault MC
    Mol Ther Oncol; 2024 Sep; 32(3):200826. PubMed ID: 39006945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors.
    Escobar-Zarate D; Liu YP; Suksanpaisan L; Russell SJ; Peng KW
    Cancer Gene Ther; 2013 Oct; 20(10):582-9. PubMed ID: 24030211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer.
    Hastie E; Grdzelishvili VZ
    J Gen Virol; 2012 Dec; 93(Pt 12):2529-2545. PubMed ID: 23052398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early steps of the virus replication cycle are inhibited in prostate cancer cells resistant to oncolytic vesicular stomatitis virus.
    Carey BL; Ahmed M; Puckett S; Lyles DS
    J Virol; 2008 Dec; 82(24):12104-15. PubMed ID: 18829743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenocarcinoma.
    Hastie E; Besmer DM; Shah NR; Murphy AM; Moerdyk-Schauwecker M; Molestina C; Roy LD; Curry JM; Mukherjee P; Grdzelishvili VZ
    J Virol; 2013 Sep; 87(18):10283-94. PubMed ID: 23864625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis C virus core protein enhances hepatocellular carcinoma cells to be susceptible to oncolytic vesicular stomatitis virus through down-regulation of HDAC4.
    Moon J; Kaowinn S; Cho IR; Min DS; Myung H; Oh S; Kaewpiboon C; Kraemer OH; Chung YH
    Biochem Biophys Res Commun; 2016 Jun; 474(3):428-434. PubMed ID: 27150631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors.
    Wollmann G; Drokhlyansky E; Davis JN; Cepko C; van den Pol AN
    J Virol; 2015 Jul; 89(13):6711-24. PubMed ID: 25878115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics of oncolytic vesicular stomatitis virus displaying tumor-targeting ligands.
    Ammayappan A; Peng KW; Russell SJ
    J Virol; 2013 Dec; 87(24):13543-55. PubMed ID: 24089573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.
    Nelson A; Gebremeskel S; Lichty BD; Johnston B
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: potential role of human papilloma virus infection.
    Le Boeuf F; Niknejad N; Wang J; Auer R; Weberpals JI; Bell JC; Dimitroulakos J
    Int J Cancer; 2012 Aug; 131(3):E204-15. PubMed ID: 22173567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retargeting Oncolytic Vesicular Stomatitis Virus to Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia.
    Betancourt D; Ramos JC; Barber GN
    J Virol; 2015 Dec; 89(23):11786-800. PubMed ID: 26378177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update.
    Felt SA; Grdzelishvili VZ
    J Gen Virol; 2017 Dec; 98(12):2895-2911. PubMed ID: 29143726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-κB-dependent autophagy.
    Shulak L; Beljanski V; Chiang C; Dutta SM; Van Grevenynghe J; Belgnaoui SM; Nguyên TL; Di Lenardo T; Semmes OJ; Lin R; Hiscott J
    J Virol; 2014 Mar; 88(5):2927-40. PubMed ID: 24371063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma.
    Blackham AU; Northrup SA; Willingham M; Sirintrapun J; Russell GB; Lyles DS; Stewart JH
    J Surg Res; 2014 Apr; 187(2):412-26. PubMed ID: 24252853
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RIG-I-mediated innate immune signaling in tumors reduces the therapeutic effect of oncolytic vesicular stomatitis virus.
    Zhang P; Han X; Tan W; Chen D; Sun Q
    Thorac Cancer; 2023 Jan; 14(3):246-253. PubMed ID: 36447430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures.
    Schäfer TE; Knol LI; Haas FV; Hartley A; Pernickel SCS; Jády A; Finkbeiner MSC; Achberger J; Arelaki S; Modic Ž; Schröer K; Zhang W; Schmidt B; Schuster P; Haferkamp S; Doerner J; Gebauer F; Ackermann M; Kvasnicka HM; Kulkarni A; Bots STF; Kemp V; Hawinkels LJAC; Poetsch AR; Hoeben RC; Ehrhardt A; Marchini A; Ungerechts G; Ball CR; Engeland CE
    EBioMedicine; 2024 Jul; 105():105219. PubMed ID: 38941955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of Nrf2 Signaling Augments Vesicular Stomatitis Virus Oncolysis via Autophagy-Driven Suppression of Antiviral Immunity.
    Olagnier D; Lababidi RR; Hadj SB; Sze A; Liu Y; Naidu SD; Ferrari M; Jiang Y; Chiang C; Beljanski V; Goulet ML; Knatko EV; Dinkova-Kostova AT; Hiscott J; Lin R
    Mol Ther; 2017 Aug; 25(8):1900-1916. PubMed ID: 28527723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms that allow vaccination against an oncolytic vesicular stomatitis virus-encoded transgene to enhance safety without abrogating oncolysis.
    AuYeung AWK; Mould RC; Stegelmeier AA; van Vloten JP; Karimi K; Woods JP; Petrik JJ; Wood GA; Bridle BW
    Sci Rep; 2021 Jul; 11(1):15290. PubMed ID: 34315959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.